Drug delivery to retina via port delivery system is efficient for patients with wet AMD
November 15th 2021In a poster presented at the American Academy of Ophthalmology 2021 annual meeting in New Orleans, Dr Mark Wieland noted that the port delivery system with ranibizumab provides drug delivery over an extended period.
DMO: Study finds faricimab provides sustained retinal stability
November 14th 2021During a presentation at the American Academy of Ophthalmology 2021 annual meeting in New Orleans, Dr Veeral Sheth presented research that found faricimab, a bispecific monoclonal antibody, provided sustained retinal stability in patients with diabetic macular oedema (DMO) compared with other retinal treatments.
Plasma metabolomic profiles could predict AMD progression
November 14th 2021Speaking at the American Academy of Ophthalmology 2021 annual meeting in New Orleans, Dr Ines Lains explained that the mechanisms of AMD progression currently remain poorly understood and the tools to predict and halt progression are limited.
Though rare, ocular surface tumours often prove deadly
November 13th 2021In a presentation at the American Academy of Ophthalmology’s 2021 annual meeting in New Orleans, Nathan Hall pointed out that an epidemiologic analysis of malignant ocular surface tumours found significant differences in geographic prevalence rates in the United States.
Study reports that optic nerve pallor is prevalent in ZIKA virus patients
November 13th 2021During a presentation at the American Academy of Ophthalmology 2021 annual meeting, Dr Denise Freitas reported that the ocular findings in infants with congenital Zika virus syndrome were similar among the affected infants and occurred frequently. The most prevalent of the findings was optic nerve pallor.
Study of bimatoprost implant reports IOP reduction for 2 years or more
November 12th 2021Dr Felipe Medeiros in a presentation at the American Academy of Ophthalmology 2021 annual meeting in New Orleans, noted that a phase 3 clinical extension study of the bimatoprost implant found that patients’ IOP was lowered and stayed low with no additional treatment or changes in their visual fields.
DMO treatment: Brolucizumab proves noninferior to aflibercept, requires fewer injections
November 12th 2021During the American Academy of Ophthalmology 2021 annual meeting in New Orleans, Dr Dilsher Dhoot reported the results of the KESTREL and KITE in which brolucizumab was compared with aflibercept for treating diabetic macular oedema.
Mitomycin C associated with increase in corneal haze after corneal crosslinking
November 12th 2021Dr Shady Awwad in a presentation at the American Academy of Ophthalmology’s 2021 annual meeting in New Orleans, pointed out that the application of mitomycin C after corneal crosslinking does not prevent development of corneal haze after the procedure and instead contributes to development of more corneal haze.
Macrophage-mediated cytokine storm associated with COVID-19 infection in diabetic patients
November 5th 2021A team of investigators from the University of Michigan may have unlocked a potential new recipe for counteracting the impact that COVID-19 has on patients with underlying disease processes such as type 2 diabetes.
PDS with ranibizumab in nAMD offers similar results to ranibizumab monthly injections
October 11th 2021Dr Arshad Khanani reported at ASRS 2021 that the Port Delivery System with ranibizumab, an investigational product that continuously delivers ranibizumab intravitreally, achieved results similar to those in patients treated with monthly ranibizumab injections for nAMD.
Universal masking may lower risk of endophthalmitis after intravitreal anti-VEGF injections
October 10th 2021During the ASRS Annual Scientific Meeting, Dr Sunir Garg reported that the risk of presumed infectious endophthalmitis following administration of anti-VEGF injections does not increase and universal masking may actually decrease the risk of culture-positive endophthalmitis.
The relationship between MIGS procedures and endophthalmitis
October 10th 2021At the ASRS 39th Annual Scientific Meeting, Dr Yoshihiro Yonekawa reported that the prevalence of endophthalmitis following MIGS is similar to the prevalence rates of endophthalmitis after other incisional glaucoma surgeries.
Beyond the VISTA/VIVID studies: Timing DMO resolution with intravitreal aflibercept
October 9th 2021Dr Rishi Singh reports on the pooled data from the VISTA and VIVID clinical trials on the use of intravitreal aflibercept injections (IAI) to treat diabetic macular oedema at the ASRS 39th Annual Scientific Meeting.